Last reviewed · How we verify
Role of Estrogen/SERMS on Cardiac Fatty Acid Metabolism (Aim #1- Human Studies)
Estrogen and progesterone are two main female sex hormones. When a woman goes through menopause, the body's production of estrogen and progesterone significantly decreases. Recent studies have shown that the breakdown of fatty acids in cardiac muscle is important in maintaining a healthy heart, and that estrogen may enhance this process. Also, cardiovascular disease (CVD) occurs more frequently in postmenopausal women than in premenopausal women. This study will determine in postmenopausal women whether estrogen increases the heart's ability to use fats as energy and whether progesterone decreases this effect.
Details
| Lead sponsor | Washington University School of Medicine |
|---|---|
| Phase | NA |
| Status | TERMINATED |
| Enrolment | 22 |
| Start date | 2004-08 |
| Completion | 2008-01 |
Conditions
- Postmenopausal Syndrome
Interventions
- Estrogen
- Progesterone
- Placebo
Primary outcomes
- Number of Participants That Had an Increase in Myocardial Fatty Acid Utilization. — 3 days
Measurements of myocardial fatty acid utilization and oxidation with C\[11\]-Palmitate and PET in healthy postmenopausal women who take either estrogen alone or with progesterone. The primary outcome measure was designed to determine prospectively whether estrogen will increase the heart's fatty acid utilization and whether progestins will attenuate this effect, in a manner similar to what was seen in an observational study of hormone replacement therapy (HRT) in post-menopausal women. To this end, we had anticipated enrolling 30 healthy post-menopausal women for assessment of cardiac fatty acid metabolism using positron emission tomography (PET) and radioactive C\[11\]-Palmitate both before and after 3 days of hormone replacement therapy. These volunteers were to be randomized to receive either estrogen alone (E) or combined estrogen/progesterone (EP).
Countries
United States